Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic ure...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2cbc80d3f2bd4235b76d715f462fab39 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2cbc80d3f2bd4235b76d715f462fab39 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2cbc80d3f2bd4235b76d715f462fab392021-12-02T01:48:43ZBenign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system1179-1470https://doaj.org/article/2cbc80d3f2bd4235b76d715f462fab392016-05-01T00:00:00Zhttps://www.dovepress.com/benign-prostatic-hyperplasia-and-new-treatment-options-ndash-a-critica-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. In particular, UroLift does not damage ejaculatory function or affect orgasmic sensation. It appears an option for men who wish to avoid long-term drug therapy, the side effects of drugs or surgery and who do not need or will not accept traditional surgical treatments. UroLift was introduced following a series of planned studies that led to US Food and Drug Administration approval in September 2013. UroLift has recently been approved by the UK National Institute for Clinical and Health Excellence (September 2015) as effective and safe and cost-effective for use in the UK health system. This review describes the device and the procedure and the evidence base that has led to those approvals. Keywords: UroLift, prostatic urethral lift, LUTS prostatic hyperplasia, minimally invasive, BPHMcNicholas TADove Medical PressarticleUroliftprostatic urethral liftLower urinary tract symptoms (LUTS)MaleBenign prostatic hyperplasiaMinimally invasive surgical procedureProstateTherapyUrethraMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2016, Iss Issue 1, Pp 115-123 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Urolift prostatic urethral lift Lower urinary tract symptoms (LUTS) Male Benign prostatic hyperplasia Minimally invasive surgical procedure Prostate Therapy Urethra Medical technology R855-855.5 |
| spellingShingle |
Urolift prostatic urethral lift Lower urinary tract symptoms (LUTS) Male Benign prostatic hyperplasia Minimally invasive surgical procedure Prostate Therapy Urethra Medical technology R855-855.5 McNicholas TA Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| description |
Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. In particular, UroLift does not damage ejaculatory function or affect orgasmic sensation. It appears an option for men who wish to avoid long-term drug therapy, the side effects of drugs or surgery and who do not need or will not accept traditional surgical treatments. UroLift was introduced following a series of planned studies that led to US Food and Drug Administration approval in September 2013. UroLift has recently been approved by the UK National Institute for Clinical and Health Excellence (September 2015) as effective and safe and cost-effective for use in the UK health system. This review describes the device and the procedure and the evidence base that has led to those approvals. Keywords: UroLift, prostatic urethral lift, LUTS prostatic hyperplasia, minimally invasive, BPH |
| format |
article |
| author |
McNicholas TA |
| author_facet |
McNicholas TA |
| author_sort |
McNicholas TA |
| title |
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| title_short |
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| title_full |
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| title_fullStr |
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| title_full_unstemmed |
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system |
| title_sort |
benign prostatic hyperplasia and new treatment options – a critical appraisal of the urolift system |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/2cbc80d3f2bd4235b76d715f462fab39 |
| work_keys_str_mv |
AT mcnicholasta benignprostatichyperplasiaandnewtreatmentoptionsndashacriticalappraisaloftheuroliftsystem |
| _version_ |
1718402886021414912 |